Likes Subject
more churn today... kanonman 09/03/20 2:25 PM
100% BUY kanonman 09/03/20 1:46 AM
WTF you talking about. 3 month chart ...... daleb2130 09/02/20 9:56 PM
Legendary beebread 09/02/20 7:01 PM
With insider buying good sized quantities you would brianslate 09/02/20 1:53 PM
yup kanonman 09/02/20 9:48 AM
Another 125,000 insider buy daleb2130 09/02/20 8:38 AM
The monster has been released, it is now TrendTrade2016 09/01/20 12:45 PM
It will sooner or later. daleb2130 09/01/20 12:40 PM
needs to stay above .60 though kanonman 09/01/20 12:39 PM
A good start today daleb2130 09/01/20 12:38 PM
the reason they are buying shares, they are TrendTrade2016 08/29/20 11:03 AM
loose...but it needs a week. TrendTrade2016 08/29/20 11:00 AM
I would say almost a lock that something daleb2130 08/28/20 10:31 PM
and more today.... always a good sign kanonman 08/28/20 9:46 PM
let it lose or let it LOOSE? kanonman 08/28/20 9:44 PM kanonman 08/28/20 9:42 PM
Handok Inc. seems to buy more shares every daleb2130 08/28/20 6:42 PM
RZLT enough is enough......time to let this lose!! TrendTrade2016 08/28/20 2:39 PM
Insiders keep buying. Always a good thing....... 5 daleb2130 08/25/20 5:01 PM
it got close...back below .50 again...really wants to kanonman 08/25/20 2:22 PM
Yes they are.... daleb2130 08/25/20 10:12 AM
HERE WE GO....60'S COMING IN FAST!!! TrendTrade2016 08/25/20 9:28 AM
GAPPA DAPPA DOO!! 53X54!!!ZOOOM!!! TrendTrade2016 08/25/20 9:15 AM
Much More daleb2130 08/24/20 8:28 PM
more to come!! TrendTrade2016 08/24/20 5:37 PM
Nice call on RZLT$. This has been a SILVER HARVEST 08/24/20 5:26 PM
RZLT little bit of consolidation up here as TrendTrade2016 08/23/20 7:40 AM
RZLT next week we see the 50's come TrendTrade2016 08/22/20 6:51 AM
bye buy NITE!!!! TrendTrade2016 08/18/20 10:05 AM
HERE WE GO...MONSTA PUSH TO .65C WHOS TrendTrade2016 08/18/20 9:52 AM
RZLT heading to .54c then 57c and the TrendTrade2016 08/18/20 6:16 AM
next week we see 54c TrendTrade2016 08/14/20 4:19 PM
Ready for 50s next week then the fun TrendTrade2016 08/14/20 3:09 PM
forming new base...the 30's are the new 20's TrendTrade2016 08/13/20 4:43 PM
pit stop The Night Stalker 08/13/20 12:10 AM
Ace! beebread 08/11/20 2:01 PM
RZLT get ready to rumble!! TrendTrade2016 08/11/20 1:11 PM
And another insider buy. Follow the money daleb2130 08/11/20 12:34 PM
nice The Night Stalker 08/08/20 12:23 AM
More insider buying. daleb2130 08/05/20 9:56 PM
Just bought in at .365 daleb2130 08/05/20 1:35 PM
PUMA bidding...NITE and CDEL stacking....classic! TrendTrade2016 08/05/20 12:45 PM
RZLT. Here we go TrendTrade2016 08/05/20 11:59 AM
beast The Night Stalker 08/05/20 12:12 AM
time to cool off The Night Stalker 07/31/20 12:40 PM
RZLT looks like .44c is setting up!! TrendTrade2016 07/30/20 4:40 AM
CDEL controls the pace...trimmed some up here!! TrendTrade2016 07/28/20 5:30 AM
beast The Night Stalker 07/28/20 12:07 AM
Lmao at the 100k wall that was at beebread 07/27/20 2:55 PM
Likes Subject

09/03/20 2:25 PM
09/03/20 1:46 AM
09/02/20 9:56 PM
09/02/20 7:01 PM
09/02/20 9:48 AM
09/02/20 8:38 AM
09/01/20 12:45 PM
09/01/20 12:40 PM
09/01/20 12:39 PM
09/01/20 12:38 PM
08/29/20 11:03 AM
08/29/20 11:00 AM
08/28/20 10:31 PM
08/28/20 9:46 PM
08/28/20 9:44 PM
08/28/20 6:42 PM
08/28/20 2:39 PM
08/25/20 10:12 AM
08/25/20 9:28 AM
08/25/20 9:15 AM
08/24/20 8:28 PM
08/24/20 5:37 PM
08/24/20 5:26 PM
08/23/20 7:40 AM
08/22/20 6:51 AM
08/18/20 10:05 AM
08/18/20 9:52 AM
08/18/20 6:16 AM
08/14/20 4:19 PM
08/14/20 3:09 PM
08/13/20 4:43 PM
The Night Stalker
08/13/20 12:10 AM
08/11/20 2:01 PM
08/11/20 1:11 PM
08/11/20 12:34 PM
The Night Stalker
08/08/20 12:23 AM
08/05/20 9:56 PM
08/05/20 1:35 PM
08/05/20 12:45 PM
08/05/20 11:59 AM
The Night Stalker
08/05/20 12:12 AM
The Night Stalker
07/31/20 12:40 PM
07/30/20 4:40 AM
07/28/20 5:30 AM
The Night Stalker
07/28/20 12:07 AM
07/27/20 2:55 PM

Rezolute Inc. (RZLT)

Posts (Today)
Posts (Total)
AntriaBioAntriaBio, Inc.
890 Santa Cruz Avenue
Menlo Park, CA 94025
P: (650) 223-5441

Reverse Merger 

Jan 7, 2013 - AntriaBio, Inc., a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the acquisition of the significant assets of PR Pharmaceuticals, Inc. and its intention to become a publicly traded company through a merger.

"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."

AntriaBio's lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.

The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery.

AB101's long duration of action is the result of our ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres. Currently available PEGylated biomolecules typically use large molecular weight PEG chains to decrease clearance and therefore reduce injection frequency. However, we use a very small molecular weight PEG for AB101 to modify the solubility of insulin and permit encapsulation of the drug into a biodegradable polymer.

After injection, the PEGylated insulin is slowly released at the injection site as the polymer microspheres are broken down by simple hydrolysis. Not only is our technology is unique, but also AB101 does not contain any new excipients and regulatory authorities have already approved numerous products using PEG or biodegradable polymers.

In addition to the proprietary technology for PEGylation of insulin and incorporation of the PEGylated insulin into biodegradable polymers, we have licensed proprietary microparticle manufacturing technology. The microsphere manufacturing process ensures production of a very tight particle size distribution with uniformly small microparticles. This is important to improve manufacturing efficiency and yields as well as to facilitate patient comfort by producing microspheres that can be injected through 25 gauge or smaller needles.


AntriaBio Appoints Two Industry Leaders to its Management Team
Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D, as AntriaBio's Chief Scientific Officer.
Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited, a medical device company based in Europe. Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.
Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia, Latin America and the Middle East. Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University.
Sankaram Mantripragada, Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009, Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013, AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.
"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe, Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.
Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than 8 patents.
Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation, now part of Abbott Vascular. Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine. Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany.


Most Liked Posts
(Last 30 Days)
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post